Expanded Access Treatment Protocol for Bulevirtide
Latest Information Update: 29 Jan 2025
Price :
$35 *
At a glance
- Drugs Bulevirtide (Primary)
- Indications Hepatitis D; Liver cirrhosis; Liver disorders
- Focus Expanded access; Therapeutic Use
- Sponsors Gilead Sciences
- 24 Jan 2025 Status changed from suspended to recruiting.
- 22 Jan 2025 New trial record